About

Studies that randomized overweight or obese men to diet and exercise programs had significantly greater increases in total testosterone levels than men who underwent calorie reduction or exercise programs alone.378, 379 It is also postulated that men who engage in quantitatively more exercise have the greatest increases in serum testosterone from baseline.378 The main purpose of testosterone therapy is to return patients to normal physiological testosterone levels and provide relief of symptoms or signs. Testosterone deficient patients should be informed that low testosterone levels place them at risk for these major cardiovascular events and clinicians should assess all testosterone deficient patients for ASCVD risk factors, both fixed (e.g., older age, male gender) and modifiable (e.g., dyslipidemia, hypertension, diabetes, current cigarette smoking). Patients with testosterone deficiency who maintain testosterone levels in the normal range while on testosterone therapy should have their PSA levels tested, utilizing a shared decision-making approach, in accordance with the AUA's Early Detection of Prostate Cancer Guideline.
Doctors use it to diagnose conditions caused by too much or too little of the hormone. Learn more about laboratory tests, reference ranges, and understanding results. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly. Having most of your testosterone bound to proteins makes sure your body doesn't use too much.
Thus, the time of day of blood sampling is an important consideration, and a blood sample drawn in the morning between 0800 and 1000h is recommended because reference ranges are generally based on morning values. A single blood sample is usually an adequate assessment of testosterone production on a given day. Presumably because of this rapid pulse frequency and a plasma half-life of min, only small testosterone fluctuations are generally observed in peripheral blood. Frequent sampling of peripheral blood in adult men reveals small frequent moment-to-moment fluctuations (10) whereas spermatic venous blood sampling reveals robust episodes of testosterone secretion occurring about once per hour (11). The secretion of testosterone is periodic with oscillations occurring over hours, days, and months.
Patients should be informed that testosterone therapy may result in improvements in erectile function, low sex drive, anemia, bone mineral density, lean body mass, and/or depressive symptoms. Clinicians should inform testosterone deficient patients that low testosterone is a risk factor for cardiovascular disease. PSA should be measured in men over 40 years of age prior to commencement of testosterone therapy to exclude a prostate cancer diagnosis. Men with testosterone deficiency who are interested in fertility should have a reproductive health evaluation performed prior to treatment. The use of validated questionnaires is not currently recommended to either define which patients are candidates for testosterone therapy or to monitor symptom response in patients on testosterone therapy. The diagnosis of low testosterone should be made only after two total testosterone measurements are taken on separate occasions with both conducted in an early morning fashion. Guidance is also given on the management of patients with cardiovascular disease, men who are interested in preserving their fertility and men who are at risk for or have prostate cancer.
Patients should be monitored for 30 minutes in a healthcare setting after injection to monitor for POME or anaphylactic-type symptoms. These recommendations, however, are not based on current testosterone pellet formulations and contrast with pharmacokinetic data available. The unique pharmacokinetic profile of testosterone pellets is due to their crystalline structure, which dissolves slowly in SQ spaces. The manufacturer-recommended dosing of IM testosterone undecanoate is 750 mg administered at weeks 0, 4, and every 10 weeks thereafter. No RCTs have compared the current formulation of IM testosterone undecanoate available in the United States to other therapies.

Female